Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Aethlon Medical, Inc. (NASDAQ: AEMD).

Full DD Report for AEMD

You must become a subscriber to view this report.


Recent News from (NASDAQ: AEMD)

Report: Developing Opportunities within AMC Networks, JELD-WEN Holding, Blueprint Medicines, Northwest Bancshares, Anika Therapeutics, and Aethlon Medical - Future Expectations, Projections Moving into 2018
NEW YORK, May 01, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of AMC Networks Inc. (NASDAQ:AMCX), JELD-WEN Holding, Inc. (NYSE:JELD), Bluep...
Source: GlobeNewswire
Date: May, 01 2018 07:55
GVC Capital and Trickle Research Announce Presenter Schedule for Rocky Mountain MicroCap Conference II in Denver on April 24, 2018
DENVER, CO / ACCESSWIRE / April 20, 2018 / GVC Capital LLC ("GVC") and Dave Lavigne at Trickle Research LLC ("Trickle Research") will host the Rocky Mountain MicroCap Conference II on April 24, 2018, in Denver at Coors Field. The Rocky Mountain MicroCap Conference II is a single track invest...
Source: ACCESSWIRE
Date: April, 18 2018 21:55
Study of Blood Test to Detect and Monitor Chronic Traumatic Encephalopathy (CTE) in Former NFL Players Set for Kick-Off in Phoenix
PHOENIX and SAN DIEGO , March 22, 2018 /PRNewswire/ -- Exosome Sciences, Inc., a diagnostic subsidiary of Aethlon Medical, Inc. (Nasdaq: AEMD), today announced the initiation of an Institutional Review Board (IRB) approved protocol for a research study involving retired NFL players...
Source: PR Newswire
Date: March, 22 2018 08:00
Midday Gainers / Losers (03/21/2018)
CALI +48% . MARA +26% . DXPE +20% . KMPH +16% . GERN +15% . TGEN +15% . NH +15% . ARNA +13% . PRTA +13% . TCCO +12% . More news on: China Auto Logistics Inc., Marathon Patent Group, Inc., DXP Enterprises, Inc., Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: March, 21 2018 12:45
Research Report Identifies Chatham Lodging Trust (REIT), Independent Bank Group, NeoGenomics, Black Knight, Aethlon Medical, and PRA Group with Renewed Outlook - Fundamental Analysis, Calculating Forward Movement
NEW YORK, March 19, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Chatham Lodging Trust (REIT) (NYSE:CLDT), Independent Bank Group, Inc (N...
Source: GlobeNewswire
Date: March, 19 2018 08:25
Aethlon Medical To Present at the American Society for Microbiology Biothreats Meeting
SAN DIEGO , Feb. 12, 2018 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, announced today that its CEO, Jim Joyce will give a presentation at the 2018 American Society for Microbiology (A...
Source: PR Newswire
Date: February, 12 2018 06:32
Aethlon Medical's (AEMD) CEO Jim Joyce on Q3 2018 Results - Earnings Call Transcript
Aethlon Medical, Inc. (AEMD) Q3 2018 Earnings Conference Call February 1, 2018 4:30 PM ET Executives John Marco – Managing Director-Core IR Jim Joyce – Chief Executive Officer Jim Frakes – Chief Financial Officer Analysts Brian Marckx – Zacks Inv...
Source: SeekingAlpha
Date: February, 01 2018 21:05
Aethlon Medical reports Q3 results
Aethlon Medical (NASDAQ: AEMD ): Q3 EPS of -$0.08 Revenue of $0.08M Press Release More news on: Aethlon Medical, Inc., Earnings news and commentary, Healthcare stocks news, ,
Source: SeekingAlpha
Date: February, 01 2018 16:20
Aethlon Medical Announces Fiscal 2018 Third Quarter Results
SAN DIEGO , Feb. 1, 2018 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, today announced results for its fiscal third quarter ended December 31, 2017 . Recent Corporate Developments ...
Source: PR Newswire
Date: February, 01 2018 16:15
Aethlon Medical to Release Third Quarter Fiscal Year 2018 Financial Results and Host Conference Call on February 1, 2018
SAN DIEGO , Jan. 29, 2018 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense today announced it will issue third quarter results for the fiscal year ended March 31, 2018 at 4:15 pm eastern time o...
Source: PR Newswire
Date: January, 29 2018 08:15

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-08-161.141.09171.141.0946,007
2018-08-151.161.1251.161.1242,376
2018-08-141.161.151.161.1321,457
2018-08-131.171.161.241.118372,829
2018-08-091.211.18361.251.17126,447

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-166,43221,48729.9344Cover
2018-08-155,23616,72731.3027Cover
2018-08-141,4539,55315.2099Cover
2018-08-135,80124,01424.1567Cover
2018-08-10121,038140,14186.3687Short

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on AEMD.


About Aethlon Medical, Inc. (NASDAQ: AEMD)

Logo for Aethlon Medical, Inc. (NASDAQ: AEMD)

The Aethlon Medical mission is to create innovative devices that address unmet medical needs in cancer, infectious disease, and other life threatening conditions. The Aethlon ADAPT system is an expansive technology platform that converges affinity drug agents and plasma membrane technology to create therapeutic filtration devices that selectively target the removal of harmful particles from the entire circulatory system. Our lead therapeutic candidate is the Aethlon Hemopurifier, a device with broad spectrum capabilities against viral pathogens and immunosuppressive cancer exosomes. In human studies, Hemopurifier therapy has provided significant viral load reductions in HIV and hepatitis C virus infected individuals without the administration of antiviral drugs. We are now focused on advancing our Hemopurifier as an adjunct strategy to improve the benefit of established infectious disease and cancer treatment regimens. Based on studies conducted by government and non government research organizations, the Hemopurifier is also a leading broad spectrum treatment candidate to address bioterror and pandemic threats.

 

Contact Information

 

 

Current Management

  • James Allen Joyce / CEO
  • Rodney S. Kenley / President
  • James Brenton Frakes / CFO
  • Richard Tullis / CSO
  • John Salvador / Director, Inv. Rel., Director, Corp. Comm.
  • Charlene Owen / Assistant to the CFO
  • James Allen Joyce / Chairman
  • Edward G. Broenniman /
  • Franklyn S. Barry, Jr. /
  • Rodney S. Kenley /
  • Cheetah S. Shah, MD /

Current Share Structure

  • Market Cap: $26,528,522 - 03/20/2018
  • Issue and Outstanding: 16,580,326 - 01/31/2018
  • Float: 4,790,301 - 05/12/2015

 


Recent Filings from (NASDAQ: AEMD)

Prospectus filed under Rule 424(b)(3)
Filing Type: 424B3Filing Source: edgar
Filing Date: April, 24 2018
Prospectus filed under Rule 424(b)(3)
Filing Type: 424B3Filing Source: edgar
Filing Date: April, 24 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 29 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 29 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 21 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 21 2018
Notice from the SEC of registration effectiveness
Filing Type: EFFECTFiling Source: edgar
Filing Date: March, 06 2018
Notice from the SEC of registration effectiveness
Filing Type: EFFECTFiling Source: edgar
Filing Date: March, 06 2018
Post-effective amendment to an S-Type filing
Filing Type: POS AMFiling Source: edgar
Filing Date: February, 20 2018
Post-effective amendment to an S-Type filing
Filing Type: POS AMFiling Source: edgar
Filing Date: February, 20 2018

 

 


Daily Technical Chart for (NASDAQ: AEMD)

Daily Technical Chart for (NASDAQ: AEMD)


Stay tuned for daily updates and more on (NASDAQ: AEMD)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: AEMD)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in AEMD is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of AEMD and does not buy, sell, or trade any shares of AEMD. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/